Plain-English translation of NCT06794229 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether and — two medications given together — can shrink advanced kidney cancer before surgery. The study is for patients with locally advanced or inoperable clear cell renal cell carcinoma (a specific type of kidney cancer). The goal is to see if this medication combination can make tumors small enough to operate on, or make surgery safer and less complex.
Some patients with advanced kidney cancer cannot have surgery right away because their tumors are too large, too complex, or in difficult locations. Doctors want to know if giving this medication combination first can shrink the cancer and make surgery possible — potentially saving more kidney function and offering patients better long-term outcomes.
You likely qualify if…
You likely don't qualify if…
You will take one pill of the first medication by mouth every day and receive the second medication by IV infusion every 2 or 4 weeks for 12 weeks. During this time you will have regular clinic visits, blood tests, and imaging scans to check how your cancer is responding. After 12 weeks, doctors will restage your cancer and decide next steps — either surgery if you are now eligible, continuing the medication if your cancer shrank but surgery is not yet possible, or switching to standard care if the cancer has gotten worse.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States